EUVIMEDEUVIMED entdecken
Editorial

Regulatory news: Olipudase alfa‐rpcp ( Xenpozyme™ ) for treatment of non‐central nervous system manifestations of acid sphingomyelinase deficiency ( ASMD ) in adult and pediatric patients— FDA Approval summary

Yuen Yi Hon, Anita Zaidi, Review Team, Kathleen Donohue, Christine Nguyen

Journal of Inherited Metabolic Disease · 2024

DOI: 10.1002/jimd.12754 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Inherited Metabolic Disease, 2024. Verfasst von Yuen Yi Hon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Sphingomyelin Phosphodiesterase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sphingomyelin PhosphodiesteraseHumansChildAdultUnited StatesDrug ApprovalUnited States Food and Drug AdministrationEnzyme Replacement TherapyRecombinant ProteinsAdolescentChild, PreschoolMaleInfantFemale

Substanzen

Sphingomyelin PhosphodiesteraseRecombinant Proteins

Autor:innen und Institutionen

  • Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Zitieren

APA

Hon, Y. Y., Zaidi, A., Review Team, Donohue, K., & Nguyen, C. (2024). Regulatory news: Olipudase alfa‐rpcp ( Xenpozyme™ ) for treatment of non‐central nervous system manifestations of acid sphingomyelinase deficiency ( ASMD ) in adult and pediatric patients— FDA Approval summary. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12754

Vancouver

Hon YY, Zaidi A, Review Team, Donohue K, Nguyen C. Regulatory news: Olipudase alfa‐rpcp ( Xenpozyme™ ) for treatment of non‐central nervous system manifestations of acid sphingomyelinase deficiency ( ASMD ) in adult and pediatric patients— FDA Approval summary. Journal of Inherited Metabolic Disease. 2024. doi:10.1002/jimd.12754

BibTeX
@article{Hon2024,
  author = {Hon, Yuen Yi and Zaidi, Anita and Review Team, Review Team and Donohue, Kathleen and Nguyen, Christine},
  title = {Regulatory news: Olipudase alfa‐rpcp ( Xenpozyme™ ) for treatment of non‐central nervous system manifestations of acid sphingomyelinase deficiency ( ASMD ) in adult and pediatric patients— FDA Approval summary},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2024},
  doi = {10.1002/jimd.12754}
}
Kostenlos starten →